What type of drug is Alunbrig?
Alunbrig (brigatinib) is an anaplastic lymphoma kinase (ALK) inhibitor used for the treatment of patients with a certain type of lung cancer called ALK-positive non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastasized).
Alunbrig was first FDA approved in 2017 for patients with ALK-positive metastatic non-small cell lung cancer who had progressed on, or were intolerant to crizotinib. In May 2020, this indication was expanded to include Alunbrig as a first-line treatment option for ALK+ NSCLC. Alunbrig is manufactured by Takeda Pharmaceuticals.
About 85% of patients with lung cancer have non-small cell lung cancer (NSCLC), with 5% of those patients having a mutation in the ALK gene (ALK-positive).
What are the ALK inhibitors?
There are several ALK inhibitors approved by the FDA for the treatment of ALK+ NSCLC. They include:
Cancer that is “ALK-positive (ALK+)” means that certain genes have rearranged in your DNA leading to an “oncogene”. An oncogene can result in uncontrolled cancer cell replication. About 5% of patients with lung cancer have ALK-positive lung cancer.
Your doctor can order an FDA-approved test to determine if you have a mutation in the ALK gene and if you are ALK+. If so, you may be able to be treated with an ALK inhibitor.
The first ALK inhibitor to be FDA approved was crizotinib (Xalkori) in 2011. Acquired resistance to crizotinib is common (due to newly acquired mutations in the ALK gene), so the second-generation ALK inhibitors such as ceritinib (Zykadia), alectinib (Alecensa), brigatinib (Alunbrig) and Lorbrena (lorlatinib) were developed to help overcome crizotinib resistance.
This is not all the information you need to know about Alunbrig (brigatinib) for safe and effective use and does not take the place of talking to your doctor about your treatment. Review the full Alunbrig information here, and discuss this information and any questions you have with your doctor or other health care provider.
Related medical questions
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions